Iteos Therapeutics Inc

About Iteos Therapeutics Inc

Iteos Therapeutics (NASDAQ:ITOS) is a biotechnology firm focused on the discovery, development, and commercialization of novel cancer immunotherapies. Its aim is to revolutionize cancer treatment by developing therapies that harness the body's immune system to fight cancer more effectively. The company's pipeline includes innovative candidates targeting the adenosine pathway and other immune checkpoint pathways, designed to address a wide range of tumors. By prioritizing patient-centered research, Iteos Therapeutics seeks to advance the scientific understanding of cancer immunotherapy and bring new treatments to market that improve the lives of those facing this challenging disease.

What is Iteos Therapeutics Inc known for?

Snapshot

2011

Year founded

167

Employees

Massachusetts, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Iteos Therapeutics Inc

EOS-448: An immune-targeting IgG1 antibody designed to enhance the immune system's ability to fight cancer.
EOS-850: Aimed at inhibiting the Adenosine A2A Receptor, potentially blocking a pathway cancer cells use to evade the immune system.
EOS-200271: An early-stage program focusing on undisclosed targets within the immune-oncology space, intended to modulate immune system components for cancer treatment.
Collaboration with GSK: Joint development of anti-cancer therapies, leveraging proprietary technologies and research capabilities.
Partnership with Merck: Focused on evaluating the combination of EOS-448 with pembrolizumab, Merck's anti-PD-1 therapy, in various cancer types.